The online home for the primary care professionals managing patients with cardiovascular disease, diabetes and related diseases.

Topic: Heart failure - Primary Care

Friday, 14 September 2018
The recent TRANSITION study shows that sacubitril/valsartan can be initiated early and safely in a wide range of heart failure (HF) patients with reduced ejection fraction (HFrEF) who have been stabilized after hospitalization due to an acute HF episode. Patients involved in the study included those with no prior experience of sacubitril/valsartan or conventional HF therapies, as well as those with prior experience of conventional HF therapies.
Thursday, 24 November 2016
The large randomised controlled trial PARADIGM-HF showed that treatment with sacubitril/valsartan (Entresto) compared with enalapril reduced the risk of hospitalisation, cardiovascular and all-cause mortality and improved symptoms in patients with heart failure with reduced ejection fraction. This article describes the key results and how they can be applied in primary care.
Category: Editorial
Monday, 21 November 2016
This article describes the use of sacubitril/valsartan – the first-in-class angiotensin receptor-neprilysin inhibitor (ARNI) in primary care and how the new drug fits in the heart failure treatment pathway. Current guidelines and case studies are also explored to provide further understanding of this latest HF treatment to enter clinical use.
Category: Editorial
Monday, 21 November 2016
This article gives an overview of sacubitril/valsartan (Entresto), a first-in-class angiotensin receptor-neprilysin inhibitor comprising valsartan, an angiotensin II receptor blocker and the neprilysin inhibitor sacubitril. The drug has been approved for the treatment of symptomatic (NYHA class (II-IV) chronic heart failure and reduced ejection fraction (HF-REF) in adults.
Category: Editorial
Tuesday, 13 July 2021
Beverley Bostock takes us through the ABC of cardiovascular disease and what primary care need to know, covering the ABC of CVD – the ambition, AF diagnosis and DOACs, BP diagnosis and management, when and how to treat cholesterol and why heart failure is firmly back on the agenda.
Category: Webinars
Friday, 30 October 2015
Heart failure (HF) is a complex clinical syndrome, characterised by symptoms including breathlessness, fatigue, reduced exercise tolerance and fluid retention. Signs and symptoms may be non-specific or difficult to elicit, and some primary healthcare professionals continue to lack confidence in their ability to identify patients with HF. A systematic approach to history-taking, examination and referral aims to help improve the accuracy of the diagnosis and ensure that HF patients are referred for specialist assessment and receive evidence-based therapies.
Category: Editorial
Friday, 30 October 2015
Despite advances in management, heart failure (HF) remains a deadly clinical syndrome, with a five-year survival of 58% compared with 93% in the matched general UK population. In this comprehensive supplement, my colleagues provide excellent reviews of all aspects of chronic and acute HF, from epidemiology, through diagnosis, lifestyle interventions, pharmacological and device therapies to implementation of current guidelines. Rather than regurgitating the content of their articles, I would like to pick out some areas worthy of thought and discussion. I will discuss challenges to clinicians in the diagnosis and management of HF, diagnostic use of natriuretic peptides (NPs), newer medical therapies and their future use, device therapies, and implementation of the evidence base into clinical practice.
Category: Editorial
Monday, 21 November 2016
This useful Back to Basics poster describes the damaging changes that take place in three key body systems when HF with reduced ejection fraction is left untreated. The sympathetic nervous system, the renin-angiotensin-aldosterone system and the natriuretic peptide system all undergo significant pathophysiological changes as HF progresses.
Category: Back to Basics
Monday, 21 November 2016
The mechanisms underlying HF are complex and involve the interaction of many hormonal and molecular signalling pathways. These pathways form the basis of many pharmacological treatments, old and new. This article will examine the factors associated with the development of HF, the pathophysiology behind it and the neurohormonal pathways involved in established HF.
Category: Editorial
Page 4 of 5

Article search and filter